{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T01:12:05Z","timestamp":1779153125126,"version":"3.51.4"},"reference-count":16,"publisher":"American Society for Clinical Investigation","issue":"18","license":[{"start":{"date-parts":[[2020,9,17]],"date-time":"2020-09-17T00:00:00Z","timestamp":1600300800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Genentech","award":["This study was funded by Genentech Inc."],"award-info":[{"award-number":["This study was funded by Genentech Inc."]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,9,17]]},"abstract":"\n BACKGROUND<\/jats:title>\n \n Baseline expression of\n FCRL5<\/jats:italic>\n , a marker of naive and memory B cells, was shown to predict response to rituximab (RTX) in rheumatoid arthritis. This study investigated baseline expression of\n FCRL5<\/jats:italic>\n as a potential biomarker of clinical response to RTX in granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA).\n <\/jats:p>\n <\/jats:sec>\n \n METHODS<\/jats:title>\n \n A previously validated quantitative PCR\u2013based (qPCR-based) platform was used to assess\n FCRL5<\/jats:italic>\n expression in patients with GPA\/MPA (RAVE trial, NCT00104299).\n <\/jats:p>\n <\/jats:sec>\n \n RESULTS<\/jats:title>\n \n Baseline\n FCRL5<\/jats:italic>\n expression was significantly higher in patients achieving complete remission (CR) at 6, 12, and 18 months, independent of other clinical and serological variables, among those randomized to RTX but not cyclophosphamide-azathioprine (CYC\/AZA). Patients with baseline\n FCRL5<\/jats:italic>\n expression \u2265 0.01 expression units (termed\n FCRL5<\/jats:italic>\n hi<\/jats:sup>\n ) exhibited significantly higher CR rates at 6, 12, and 18 months as compared with\n FCRL5<\/jats:italic>\n lo<\/jats:sup>\n subjects (84% versus 57% [\n P<\/jats:italic>\n = 0.016], 68% versus 40% [\n P<\/jats:italic>\n = 0.02], and 68% versus 29% [\n P<\/jats:italic>\n = 0.0009], respectively).\n <\/jats:p>\n <\/jats:sec>\n \n CONCLUSION<\/jats:title>\n \n Our data taken together suggest that\n FCRL5<\/jats:italic>\n is a biomarker of B cell lineage associated with increased achievement and maintenance of complete remission among patients treated with RTX and warrant further investigation in a prospective manner.\n <\/jats:p>\n <\/jats:sec>\n \n FUNDING<\/jats:title>\n The analysis for this study was funded by Genentech Inc.<\/jats:p>\n <\/jats:sec>","DOI":"10.1172\/jci.insight.136180","type":"journal-article","created":{"date-parts":[[2020,8,25]],"date-time":"2020-08-25T12:11:16Z","timestamp":1598357476000},"source":"Crossref","is-referenced-by-count":13,"title":["Fc receptor-like 5 and anti-CD20 treatment response in granulomatosis with polyangiitis and microscopic polyangiitis"],"prefix":"10.1172","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7413-0949","authenticated-orcid":true,"given":"Kasia","family":"Owczarczyk","sequence":"first","affiliation":[{"name":"Department of Cancer Imaging, King\u2019s College London, London, United Kingdom."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew D.","family":"Cascino","sequence":"additional","affiliation":[{"name":"Genentech, South San Francisco, California, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cecile","family":"Holweg","sequence":"additional","affiliation":[{"name":"Genentech, South San Francisco, California, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaik W.","family":"Tew","sequence":"additional","affiliation":[{"name":"Genentech, South San Francisco, California, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6518-286X","authenticated-orcid":true,"given":"Ward","family":"Ortmann","sequence":"additional","affiliation":[{"name":"Genentech, South San Francisco, California, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy","family":"Behrens","sequence":"additional","affiliation":[{"name":"Genentech, South San Francisco, California, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Schindler","sequence":"additional","affiliation":[{"name":"Hoffmann \u2013 La Roche, Basel, Switzerland."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carol A.","family":"Langford","sequence":"additional","affiliation":[{"name":"Cleveland Clinic, Cleveland, Ohio, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E. William","family":"St. Clair","sequence":"additional","affiliation":[{"name":"Duke University Medical Center, Durham, North Carolina, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9284-7345","authenticated-orcid":true,"given":"Peter A.","family":"Merkel","sequence":"additional","affiliation":[{"name":"University of Pennsylvania, Philadelphia, Pennsylvania, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Spiera","sequence":"additional","affiliation":[{"name":"Hospital for Special Surgery, New York, New York, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip","family":"Seo","sequence":"additional","affiliation":[{"name":"Johns Hopkins University, Baltimore, Maryland, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cees G.M.","family":"Kallenberg","sequence":"additional","affiliation":[{"name":"University Medical Center Groningen, Groningen, Netherlands."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6559-1206","authenticated-orcid":true,"given":"Ulrich","family":"Specks","sequence":"additional","affiliation":[{"name":"Mayo Clinic College of Medicine and Science, Rochester, Minnesota, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noha","family":"Lim","sequence":"additional","affiliation":[{"name":"Immune Tolerance Network (ITN), Seattle, Washington, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Stone","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital, Boston, Massachusetts, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Brunetta","sequence":"additional","affiliation":[{"name":"Genentech, South San Francisco, California, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0203-0129","authenticated-orcid":true,"given":"Marco","family":"Prunotto","sequence":"additional","affiliation":[{"name":"Hoffmann \u2013 La Roche, Basel, Switzerland."},{"name":"School of Pharmaceutical Sciences, University of Geneva, Geneva, Switzerland."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"the RAVE-ITN Research Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"232","published-online":{"date-parts":[[2020,9,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2014.103"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0909905"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1213277"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-208073"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-143-9-200511010-00005"},{"issue":"101","key":"B6","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3002432","article-title":"A plasmablast biomarker for nonresponse to antibody therapy to CD20 in rheumatoid arthritis","volume":"3","author":"Owczarczyk","year":"2011","journal-title":"Sci Transl Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0703354104"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1202860"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1501027"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12659"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/art.38222"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2016.04.001"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1004894"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2005.08.004"},{"key":"B15","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-015-0778-z","article-title":"Reanalysis of the Rituximab in ANCA-Associated Vasculitis trial identifies granulocyte subsets as a novel early marker of successful treatment","volume":"17","author":"Nasrallah","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200104)44:4<912::AID-ANR148>3.0.CO;2-5"}],"container-title":["JCI Insight"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/insight.jci.org\/articles\/view\/136180\/files\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:52:59Z","timestamp":1779151979000},"score":1,"resource":{"primary":{"URL":"https:\/\/insight.jci.org\/articles\/view\/136180"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,17]]},"references-count":16,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2020,9,17]]},"published-print":{"date-parts":[[2020,9,17]]}},"alternative-id":["10.1172\/jci.insight.136180"],"URL":"https:\/\/doi.org\/10.1172\/jci.insight.136180","relation":{},"ISSN":["2379-3708"],"issn-type":[{"value":"2379-3708","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,17]]},"article-number":"e136180"}}